May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Topical Cobalt Chelate Ctc-96 for Treatment of Adenovirus Conjunctivitis in a Rabbit Model
Author Affiliations & Notes
  • S.P. Epstein
    Ophthalmology Box 1183, Mount Sinai Medical Center, New York, NY, United States
  • Y.Y. Pashinsky
    Ophthalmology Box 1183, Mount Sinai Medical Center, New York, NY, United States
  • I. Winicov
    Redox Pharmaceutical Corporation, Greenvale, NY, United States
  • P.A. Asbell
    Redox Pharmaceutical Corporation, Greenvale, NY, United States
  • Footnotes
    Commercial Relationships  S.P. Epstein, Redox Pharmaceutical Corporation C, R; Y.Y. Pashinsky, Redox Pharmaceutical Corporation C; I. Winicov, Redox Pharmaceutical Corporation E; P.A. Asbell, Redox Pharmaceutical Corporation C, R.
  • Footnotes
    Support  Supported by Redox Pharm., NCI(SBIR) #CA62697, NEI#5P30EYO1867 & Research to Prevent Blindness, Inc.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 4650. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S.P. Epstein, Y.Y. Pashinsky, I. Winicov, P.A. Asbell; Topical Cobalt Chelate Ctc-96 for Treatment of Adenovirus Conjunctivitis in a Rabbit Model . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4650.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Adenovirus (Ad), one of the most common external ocular viral infections worldwide, is associated with significant morbidity and visual disturbances and is highly contagious. Currently, there is no topical antiviral treatment available for adenovirus. We have previously shown that topical tetradentate CoIII chelates can be effective against Herpes Simplex Virus (HSV) keratitis in a rabbit model, that human Adenovirus type 5 (Ad5) has the ability to replicate in rabbits and rabbit cells and that CTC-96 is effective against Ad5 in tissue culture. We now look at the efficacy of CTC-96 in treating ocular Ad infections in a rabbit model. Methods: Normal 3-5 lb NZW rabbits were intracorneally infected with Ad5. After 8 days when ocular disease developed, the animals were arbitrarily divided into groups receiving for 21 days: 1) placebo treatment (normal saline), 9x/day ("-"); 2) CTC-96, 50µg/ml, 9x/day ("50/9"); CTC-96, 50µg/ml, 6x/day ("50/6"); CTC-96, 25µg/ml, 6x/day ("25/6"). Animals were followed in a masked/blinded fashion and monitored for severity/resolution of the conjunctivitis via biomicroscropic examination as well as in conjunctival adenovirus cultures followed by a standardized plaque assay. Results: CTC-96 at 50µg/ml was effective against Ad5, eliminating virus by day 10 in both of the dosing frequencies evaluated, whereas viral clearance was not achieved until day 21 in the sham-treated eyes. CTC-96 at 25µg/ml was only marginally effective. Conclusions: 1) In rabbits, infection with Ad5 produced mainly conjunctivitis with rare slight, small changes in the cornea and/or stroma. 2) Iritis was occasionally seen. 3) Conjunctivitis seen in all eyes by day 8 post-innoculum. 4) Resolution fastest in treatment group "50/9" where most animals resolved by day 21 post-treatment initiation (pt): "50/9" > "50/6" > "25/6" > "-". 5) Little corneal or intra-ocular changes noted in any of the groups. In conclusion, cobalt chelates (CTC-96) were effective in reducing the degree and length of conjunctivitis in rabbit eyes infected with Adenovirus.

Keywords: adenovirus • antiviral drugs • animal model 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×